Sialyl-Tn in Cancer: (How) Did We Miss the Target?

Detalhes bibliográficos
Autor(a) principal: Sylvain , Julien
Data de Publicação: 2012
Outros Autores: Videira, Paula A, Delannoy, Philippe
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.3390/biom2040435
Resumo: http://www.mdpi.com/2218-273X/2/4/435
id RCAP_a2ff779c42bd7a03461b38f459cd6786
oai_identifier_str oai:run.unl.pt:10362/23346
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Sialyl-Tn in Cancer: (How) Did We Miss the Target?ST6GalNAc Icancer immunotherapyTheratopeO-glycanSialyl-Tn antigenSialyl-Tn antigenO-glycanST6GalNAc ITheratopecancer immunotherapySDG 3 - Good Health and Well-beinghttp://www.mdpi.com/2218-273X/2/4/435Sialyl-Tn antigen (STn) is a short O-glycan containing a sialic acid residue a2,6-linked to GalNAca-O-Ser/Thr. The biosynthesis of STn is mediated by a specific sialyltransferase termed ST6GalNAc I, which competes with O-glycans elongating glycosyltransferases and prevents cancer cells from exhibiting longer O-glycans. While weakly expressed by fetal and normal adult tissues, STn is expressed by more than 80% of human carcinomas and in all cases, STn detection is associated with adverse outcome and decreased overall survival for the patients. Because of its pan-carcinoma expression associated with an adverse outcome, an anti-cancer vaccine, named Theratope, has been designed towards the STn epitope. In spite of the great enthusiasm around this immunotherapy, Theratope failed on Phase III clinical trial. However, in lieu of missing this target, one should consider to revise the Theratope design and the actual facts. In this review, we highlight the many lessons that can be learned from this failure from the immunological standpoint, as well as from the drug design and formulation and patient selection. Moreover, an irrefutable knowledge is arising from novel immunotherapies targeting other carbohydrate antigens and STn carrier proteins, such as MUC1, that will warrantee the future development of more successful anti-STn immunotherapy strategies.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)Centro de Estudos de Doenças Crónicas (CEDOC)RUNSylvain , JulienVideira, Paula ADelannoy, Philippe2017-09-18T22:00:28Z2012-10-112012-10-11T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article32application/pdfhttps://doi.org/10.3390/biom2040435eng2218-273XPURE: 155930http://www.mdpi.com/2218-273X/2/4/435https://doi.org/10.3390/biom2040435info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T04:11:35Zoai:run.unl.pt:10362/23346Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:27:45.892736Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Sialyl-Tn in Cancer: (How) Did We Miss the Target?
title Sialyl-Tn in Cancer: (How) Did We Miss the Target?
spellingShingle Sialyl-Tn in Cancer: (How) Did We Miss the Target?
Sylvain , Julien
ST6GalNAc I
cancer immunotherapy
Theratope
O-glycan
Sialyl-Tn antigen
Sialyl-Tn antigen
O-glycan
ST6GalNAc I
Theratope
cancer immunotherapy
SDG 3 - Good Health and Well-being
title_short Sialyl-Tn in Cancer: (How) Did We Miss the Target?
title_full Sialyl-Tn in Cancer: (How) Did We Miss the Target?
title_fullStr Sialyl-Tn in Cancer: (How) Did We Miss the Target?
title_full_unstemmed Sialyl-Tn in Cancer: (How) Did We Miss the Target?
title_sort Sialyl-Tn in Cancer: (How) Did We Miss the Target?
author Sylvain , Julien
author_facet Sylvain , Julien
Videira, Paula A
Delannoy, Philippe
author_role author
author2 Videira, Paula A
Delannoy, Philippe
author2_role author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
Centro de Estudos de Doenças Crónicas (CEDOC)
RUN
dc.contributor.author.fl_str_mv Sylvain , Julien
Videira, Paula A
Delannoy, Philippe
dc.subject.por.fl_str_mv ST6GalNAc I
cancer immunotherapy
Theratope
O-glycan
Sialyl-Tn antigen
Sialyl-Tn antigen
O-glycan
ST6GalNAc I
Theratope
cancer immunotherapy
SDG 3 - Good Health and Well-being
topic ST6GalNAc I
cancer immunotherapy
Theratope
O-glycan
Sialyl-Tn antigen
Sialyl-Tn antigen
O-glycan
ST6GalNAc I
Theratope
cancer immunotherapy
SDG 3 - Good Health and Well-being
description http://www.mdpi.com/2218-273X/2/4/435
publishDate 2012
dc.date.none.fl_str_mv 2012-10-11
2012-10-11T00:00:00Z
2017-09-18T22:00:28Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.3390/biom2040435
url https://doi.org/10.3390/biom2040435
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2218-273X
PURE: 155930
http://www.mdpi.com/2218-273X/2/4/435
https://doi.org/10.3390/biom2040435
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 32
application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799137904970170368

Registros relacionados